Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

17 beta-estradiol for postmenopausal estrogen replacement therapy.

K C Nichols, L Schenkel, H Benson

    Obstetrical & Gynecological Survey
    |April 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Effects of gender and marital status on somatic symptoms of patients attending a mind/body medicine clinic.

    Behavioral medicine (Washington, D.C.)·2001
    Same author

    Somatization and symptom reduction through a behavioral medicine intervention in a mind/body medicine clinic.

    Behavioral medicine (Washington, D.C.)·2001
    Same author

    Depression and education as predicting factors for completion of a behavioral medicine intervention in a mind/body medicine clinic.

    Behavioral medicine (Washington, D.C.)·2001
    Same author

    The placebo effect and relaxation response: neural processes and their coupling to constitutive nitric oxide.

    Brain research. Brain research reviews·2001
    Same author

    Nitric oxide inhibits norepinephrine stimulated contraction of human internal thoracic artery and rat aorta.

    Pharmacological research·2001
    Same author

    Anxiety is a good indicator for somatic symptom reduction through behavioral medicine intervention in a mind/body medicine clinic.

    Psychotherapy and psychosomatics·2001

    Estrogen deficiency after menopause causes hot flashes and bone loss. Effective estrogen replacement therapy should maintain estradiol levels between 35-55 pg/ml for symptom relief and osteoporosis prevention.

    Area of Science:

    • Endocrinology
    • Menopause Research
    • Pharmacology

    Background:

    • Postmenopausal women experience estrogen deficiency, leading to symptoms like hot flashes and bone density loss.
    • Oral estrogen therapy, while common, can cause undesirable side effects due to liver metabolism.
    • Alternative parenteral routes aim to improve estrogen delivery and reduce side effects.

    Purpose of the Study:

    • To review the literature on estrogen replacement therapy for menopausal symptoms.
    • To determine the relationship between estradiol plasma levels and therapeutic efficacy.
    • To identify optimal estradiol levels for treating menopausal symptoms and preventing osteoporosis.

    Main Methods:

    • Literature review of studies on various estrogen administration routes (oral, parenteral, implants, vaginal rings).

    Related Experiment Videos

  • Analysis of estradiol and estrone plasma concentrations in response to different regimens.
  • Correlation of plasma hormone levels with symptom relief (hot flashes) and bone density (osteoporosis prevention).

    • Main Results:

    • Parenteral estrogen administration, implants, and vaginal rings offer improved plasma concentration profiles compared to oral routes.
    • Daily estradiol doses of 0.2 mg or less are effective in reducing hot flashes.
    • Therapeutic efficacy for menopausal symptoms correlates with maintaining estradiol plasma levels of 35-55 pg/ml.

    Conclusions:

    • Estrogen replacement therapy efficacy is linked to achieving adequate estradiol plasma levels.
    • Parenteral or sustained-release estradiol regimens can effectively manage menopausal symptoms.
    • Further research may explore optimal estradiol levels for long-term bone health in postmenopausal women.